Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT05514106
PHASE4

MIBG in Aging and Neurologic Disorders

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.

Official title: Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease

Key Details

Gender

All

Age Range

40 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2023-05-08

Completion Date

2026-09

Last Updated

2025-07-10

Healthy Volunteers

Yes

Interventions

DRUG

meta-iodobenzylguanidine (MIBG) (123I)

1 administration of 123I-MIBG for a single SPECT scan

DIAGNOSTIC_TEST

123I-MIBG scintigraphy

SPECT scan involving 123I-MIBG as the ligand

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States